SinoMab BioScience Limited
中國抗體製藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 3681)

VOLUNTARY ANNOUNCEMENT
UPDATE IN CLINICAL PROGRESS

Reference is made to the announcements of SinoMab BioScience Limited (中國抗體製藥有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") dated 16 February 2022, 14 March 2022, 15 June 2022 and the interim results announcement dated 22 August 2022 in relation to the latest research and development progress of one of the Group's key products, SM17.

The board ("**Board**") of directors of the Company is pleased to announced that, as of 31 August 2022, 22 subjects have been enrolled in the Phase I First-In-Human (FIH) clinical trial in the U.S. The subjects are currently in normal condition.

The phase I study is a Single Ascending Dose (SAD) and Multiple Ascending Doses (MAD) to investigate the safety, tolerability, and pharmacokinetics of SM17 in healthy subjects. The Investigational New Drug ("**IND**") application, for the treatment of patients with asthma, was approved by the U.S. Food and Drug Administration in March 2022.

With respect to the clinical progress of other products of the Group, the Company has recently achieved considerable progress. The Board is confident in the future development of the Company and confirmed that the Group's business operation remains normal.

For the Company's flagship product SM03 (Suciraslimab), the preliminary result for primary endpoint of Phase III study at week 24 is expected in the third quarter of 2022 and the readout of the final study result for both safety and efficacy at week 52 is expected in the first quarter of 2023. The Company plans to submit the New Drug Application to the National Medical Products Administration (the "**NMPA**") of the People's Republic of China in the first half of 2023 and expects to commercialise Suciraslimab in the second half of 2023 at the earliest.

As for the Company's key product SN1011, it currently obtained 4 IND approvals from the NMPA for the treatment of systemic lupus erythematosus, pemphigus, multiple sclerosis and neuromyelitis optica spectrum disorder ("**NMOSD**"). The IND approval for the treatment of NMOSD would enable the Company to initiate the Phase II/III clinical study to evaluate the efficacy and safety of SN1011 in patients with NMOSD in China. The planned first patient enrollment is in the first quarter of 2023.

All clinical trials of the Company are progressing efficiently. The Company will continue to strive to develop its products pipeline and create value for the shareholders.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 5 September 2022

As at the date of this announcement, the executive director is Dr. Shui On LEUNG, the non-executive directors are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.